secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medtronic plc (MDT)
CIK:        0001613103
Form:       8-K
Filed at:   2024-08-20T23:59:59+00:00
Accession:  0001613103-24-000140
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medtronic Q1 FY25: revenue $7.9B (+2.8%), GAAP EPS $0.80, non-GAAP EPS $1.23; raises FY25 guidance
--------------------------------------------------------------------------------

- Revenue $7.915B (adjusted $8.004B), up 5.3% organic; GAAP EPS $0.80, non-GAAP EPS $1.23 (+8% constant currency).
- Raises FY25 organic revenue growth guidance to 4.5%-5% (from 4-5%) and non-GAAP EPS guidance to $5.42-$5.50.
- Cardiovascular $3.007B (+6.9% organic) driven by CRM and PFA; Neuroscience $2.317B (+5.3% organic) with Neuromodulation up low-double digits.
- Diabetes $647M (+12.6% organic) on MiniMed 780G; Simplera CGM FDA approved, Abbott partnership for future integrated CGM.
- Medical Surgical $1.996B (+1.0% organic) with SE low-single digit growth and ACM flat.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613103/000161310324000140/0001613103-24-000140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613103/000161310324000140/mdt-20240820.htm
  HTML page:      https://secwatch.observer/filing/0001613103-24-000140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer